We're looking to see if a new drug called zanidatamab, when used with chemotherapy, is safe and works well in treating early-stage HER2-positive breast cancer. If zanidatamab is effective, it might offer a better treatment option compared to the usual methods used today in battling this cancer type.
Thank you for your interest, but this study will start enrolling soon.
United States (Nationwide)
Stephen Kimani
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Breast)
25-3092
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
